Literature DB >> 22449646

Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression.

Dana L McMakin1, Thomas M Olino, Giovanna Porta, Laura J Dietz, Graham Emslie, Gregory Clarke, Karen Dineen Wagner, Joan R Asarnow, Neal D Ryan, Boris Birmaher, Wael Shamseddeen, Taryn Mayes, Betsy Kennard, Anthony Spirito, Martin Keller, Frances L Lynch, John F Dickerson, David A Brent.   

Abstract

OBJECTIVE: To identify symptom dimensions of depression that predict recovery among selective serotonin reuptake inhibitor (SSRI) treatment-resistant adolescents undergoing second-step treatment.
METHOD: The Treatment of Resistant Depression in Adolescents (TORDIA) trial included 334 SSRI treatment-resistant youth randomized to a medication switch, or a medication switch plus CBT. This study examined five established symptom dimensions (Child Depression Rating Scale-Revised) at baseline as they predicted recovery over 24 weeks of acute and continuation treatment. The two indices of recovery that were evaluated were time to remission and number of depression-free days.
RESULTS: Multivariate analyses examining all five depression symptom dimensions simultaneously indicated that anhedonia was the only dimension to predict a longer time to remission, and also the only dimension to predict fewer depression-free days. In addition, when anhedonia and CDRS-total score were evaluated simultaneously, anhedonia continued to uniquely predict longer time to remission and fewer depression-free days.
CONCLUSIONS: Anhedonia may represent an important negative prognostic indicator among treatment-resistant depressed adolescents. Further research is needed to elucidate neurobehavioral underpinnings of anhedonia, and to test treatments that target anhedonia in the context of overall treatment of depression.
Copyright © 2012 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22449646      PMCID: PMC3536476          DOI: 10.1016/j.jaac.2012.01.011

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  35 in total

1.  Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder.

Authors:  B Birmaher; D A Brent; D Kolko; M Baugher; J Bridge; D Holder; S Iyengar; R E Ulloa
Journal:  Arch Gen Psychiatry       Date:  2000-01

2.  Can people feel happy and sad at the same time?

Authors:  J T Larsen; A P McGraw; J T Cacioppo
Journal:  J Pers Soc Psychol       Date:  2001-10

3.  Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data.

Authors:  J Kaufman; B Birmaher; D Brent; U Rao; C Flynn; P Moreci; D Williamson; N Ryan
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1997-07       Impact factor: 8.829

Review 4.  Report by the ACNP Task Force on response and remission in major depressive disorder.

Authors:  A John Rush; Helena C Kraemer; Harold A Sackeim; Maurizio Fava; Madhukar H Trivedi; Ellen Frank; Philip T Ninan; Michael E Thase; Alan J Gelenberg; David J Kupfer; Darrel A Regier; Jerrold F Rosenbaum; Oakley Ray; Alan F Schatzberg
Journal:  Neuropsychopharmacology       Date:  2006-06-21       Impact factor: 7.853

5.  The role of positive emotions in positive psychology. The broaden-and-build theory of positive emotions.

Authors:  B L Fredrickson
Journal:  Am Psychol       Date:  2001-03

6.  Predictors of treatment efficacy in a clinical trial of three psychosocial treatments for adolescent depression.

Authors:  D A Brent; D J Kolko; B Birmaher; M Baugher; J Bridge; C Roth; D Holder
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1998-09       Impact factor: 8.829

7.  Behavioral activation and inhibition systems and the severity and course of depression.

Authors:  Karen L Kasch; Jonathan Rottenberg; Bruce A Arnow; Ian H Gotlib
Journal:  J Abnorm Psychol       Date:  2002-11

8.  Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo.

Authors:  Rajiv Mallick; Jieling Chen; A Richard Entsuah; Alan F Schatzberg
Journal:  J Clin Psychiatry       Date:  2003-03       Impact factor: 4.384

9.  Sadness and amusement reactivity differentially predict concurrent and prospective functioning in major depressive disorder.

Authors:  Jonathan Rottenberg; Karen L Kasch; James J Gross; Ian H Gotlib
Journal:  Emotion       Date:  2002-06

10.  Predicting time to recovery among depressed adolescents treated in two psychosocial group interventions.

Authors:  Paul Rohde; John R Seeley; Noah K Kaufman; Gregory N Clarke; Eric Stice
Journal:  J Consult Clin Psychol       Date:  2006-02
View more
  127 in total

1.  Acute behavioral interventions and outpatient treatment strategies with suicidal adolescents.

Authors:  Kimberly H McManama O'Brien; Jonathan B Singer; Mary LeCloux; Yovanska Duarté-Vélez; Anthony Spirito
Journal:  Int J Behav Consult Ther       Date:  2014

2.  Co-Occurring Depressive and Substance Use Disorders in Adolescents: An Examination of Reward Responsiveness During Treatment.

Authors:  Kathryn D Boger; Randy P Auerbach; Pia Pechtel; Alisa B Busch; Shelly F Greenfield; Diego A Pizzagalli
Journal:  J Psychother Integr       Date:  2014-06

3.  Intolerance of uncertainty mediates reduced reward anticipation in major depressive disorder.

Authors:  Brady D Nelson; Stewart A Shankman; Greg H Proudfit
Journal:  J Affect Disord       Date:  2014-02-12       Impact factor: 4.839

4.  Childhood trauma exposure disrupts the automatic regulation of emotional processing.

Authors:  Hilary A Marusak; Kayla R Martin; Amit Etkin; Moriah E Thomason
Journal:  Neuropsychopharmacology       Date:  2015-03-13       Impact factor: 7.853

5.  Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template.

Authors:  Soumava Santra; Horrick Sharma; Seenuvasan Vedachalam; Tamara Antonio; Maarten Reith; Aloke Dutta
Journal:  Bioorg Med Chem       Date:  2014-12-25       Impact factor: 3.641

6.  Test-retest & familial concordance of MDD symptoms.

Authors:  Ariela J E Kaiser; Carter J Funkhouser; Vijay A Mittal; Sebastian Walther; Stewart A Shankman
Journal:  Psychiatry Res       Date:  2020-07-20       Impact factor: 3.222

7.  Social anhedonia in major depressive disorder: a symptom-specific neuroimaging approach.

Authors:  Verena Enneking; Pia Krüssel; Dario Zaremba; Katharina Dohm; Dominik Grotegerd; Katharina Förster; Susanne Meinert; Christian Bürger; Fanni Dzvonyar; Elisabeth J Leehr; Joscha Böhnlein; Jonathan Repple; Nils Opel; Nils R Winter; Tim Hahn; Ronny Redlich; Udo Dannlowski
Journal:  Neuropsychopharmacology       Date:  2018-11-27       Impact factor: 7.853

Review 8.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

Review 9.  Assessing anhedonia in depression: Potentials and pitfalls.

Authors:  Sakina J Rizvi; Diego A Pizzagalli; Beth A Sproule; Sidney H Kennedy
Journal:  Neurosci Biobehav Rev       Date:  2016-03-06       Impact factor: 8.989

Review 10.  The promise of ketamine for treatment-resistant depression: current evidence and future directions.

Authors:  Kaitlin E DeWilde; Cara F Levitch; James W Murrough; Sanjay J Mathew; Dan V Iosifescu
Journal:  Ann N Y Acad Sci       Date:  2015-02-03       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.